Paper25758528
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Niederst MJ and 26 others. Nat Commun, 2015. Cited by 558 papers, by iCite.
Cite this record
ConductScience Library. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Papers, record 25758528. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25758528
- Cell line
- MGH1213 papers
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records11
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Cell lines11
- MGH121Cellosaurus cites the paper3 papers
- MGH134Cellosaurus cites the paper3 papers
- MGH125Cellosaurus cites the paper2 papers
- MGH157Cellosaurus cites the paper2 papers
- MGH119Cellosaurus cites the paper1 paper
- MGH119-RCellosaurus cites the paper1 paper
- MGH126Cellosaurus cites the paper1 paper
- MGH131-1Cellosaurus cites the paper1 paper
- MGH131-2Cellosaurus cites the paper1 paper
- MGH141Cellosaurus cites the paper1 paper
- MGH156Cellosaurus cites the paper1 paper
Topics26
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenocarcinoma | Major topic |
| Antineoplastic Agents | Major topic |
| Carcinoma, Non-Small-Cell Lung | Major topic |
| ErbB Receptors | Major topic |
| Lung Neoplasms | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Retinoblastoma Protein | Major topic |
| Small Cell Lung Carcinoma | Major topic |
| Adenocarcinoma of Lung | |
| Afatinib | |
| Aniline Compounds | |
| Cell Line, Tumor | |
| Disease Progression | |
| Drug Resistance, Neoplasm | |
| Erlotinib Hydrochloride | |
| Gefitinib | |
| Gene Expression Regulation, Neoplastic | |
| Humans | |
| Lung | |
| Mutation | |
| Proto-Oncogene Proteins c-bcl-2 | |
| Quinazolines | |
| Recurrence | |
| Signal Transduction | |
| Sulfonamides | |
| bcl-X Protein |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P50CA090578 | NCI NIH HHS | United States | P50CA090578 | PubMed and NIH | NIH RePORTER |
| R01 CA137008 | NCI NIH HHS | United States | R01CA137008 | PubMed and NIH | NIH RePORTER |
| R01CA137008 | NCI NIH HHS | United States | R01CA137008 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| P50 CA090578 | NCI NIH HHS | United States | P50CA090578 | PubMed and NIH | NIH RePORTER |
| R21 CA156000 | NCI NIH HHS | United States | R21CA156000 | PubMed and NIH | NIH RePORTER |
| 5R21CA156000 | NCI NIH HHS | United States | R21CA156000 | PubMed and NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03419286 | Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment | Background |
Source ClinicalTrials.gov
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20573926 | Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20573926 | PubMed |
| 2 | 20624269 | MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. | J Exp Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20624269 | PubMed |
| 3 | 21098728 | BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. | Sci Signal | 2010 | https://conductscience.org/library/papers/21098728 | PubMed |
| 4 | 21178714 | Epidermal growth factor receptor mutations in small cell lung cancer: a brief report. | J Thorac Oncol | 2011 | https://conductscience.org/library/papers/21178714 | PubMed |
| 5 | 21316603 | A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. | Cancer Cell | 2011 | https://conductscience.org/library/papers/21316603 | PubMed |
| 6 | 21430269 | Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. | Sci Transl Med | 2011 | https://conductscience.org/library/papers/21430269 | PubMed |
| 7 | 21791641 | A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. | Cancer Res | 2011 | https://conductscience.org/library/papers/21791641 | PubMed |
| 8 | 20022809 | Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. | Lancet Oncol | 2010 | https://conductscience.org/library/papers/20022809 | PubMed |
| 9 | 21565397 | Small-cell lung cancer. | Lancet | 2011 | https://conductscience.org/library/papers/21565397 | PubMed |
| 10 | 22071650 | Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. | Ann Oncol | 2011 | https://conductscience.org/library/papers/22071650 | PubMed |
| 11 | 22277784 | Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. | Sci Transl Med | 2012 | https://conductscience.org/library/papers/22277784 | PubMed |
| 12 | 22460902 | Systematic identification of genomic markers of drug sensitivity in cancer cells. | Nature | 2012 | https://conductscience.org/library/papers/22460902 | PubMed |
| 13 | 22460905 | The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. | Nature | 2012 | https://conductscience.org/library/papers/22460905 | PubMed |
| 14 | 22496272 | Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22496272 | PubMed |
| 15 | 22961666 | Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. | Cancer Discov | 2012 | https://conductscience.org/library/papers/22961666 | PubMed |
| 16 | 22941188 | Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. | Nat Genet | 2012 | https://conductscience.org/library/papers/22941188 | PubMed |
| 17 | 22941189 | Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. | Nat Genet | 2012 | https://conductscience.org/library/papers/22941189 | PubMed |
| 18 | 23401451 | Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23401451 | PubMed |
| 19 | 23470965 | Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23470965 | PubMed |
| 20 | 23816960 | Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23816960 | PubMed |
Cited by401
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 558 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42953404 | Metabolic control of methylation landscapes in cancer growth and plasticity: targeting the epigenetic-metabolic axis with natural compounds and emerging therapies. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42953404 | PubMed |
| 42844350 | Cell plasticity in cancer and therapy resistance. | Exp Mol Med | 2026 | https://conductscience.org/library/papers/42844350 | PubMed |
| 42836273 | Genes, fuel, and fate in lung cancer. | Biochem Soc Trans | 2026 | https://conductscience.org/library/papers/42836273 | PubMed |
| 42816600 | Lineage identity governs oncogene dependence in mouse NSCLC models of KRAS inhibitor resistance. | Nat Genet | 2026 | https://conductscience.org/library/papers/42816600 | PubMed |
| 42761714 | Lineage plasticity and immune invisibility in primary SCLC and LUAD-to-SCLC transformation: antigen presentation loss and therapeutic redirection. | Front Immunol | 2026 | https://conductscience.org/library/papers/42761714 | PubMed |
| 42757013 | Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma. | Front Genet | 2026 | https://conductscience.org/library/papers/42757013 | PubMed |
| 42724635 | Advanced and underlying therapeutic strategies in transformed small cell lung cancer. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42724635 | PubMed |
| 42611544 | Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42611544 | PubMed |
| 42603101 | Epigenetic reprogramming of lineage switching in cancer. | FEBS Lett | 2026 | https://conductscience.org/library/papers/42603101 | PubMed |
| 42572587 | Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer. | iScience | 2026 | https://conductscience.org/library/papers/42572587 | PubMed |
| 42570967 | Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42570967 | PubMed |
| 42512348 | Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512348 | PubMed |
| 42490143 | PAX5 modulates vascularization and contributes to neuroendocrine lineage transition during carcinoma progression. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42490143 | PubMed |
| 42483566 | Near Infrared Photoimmunotherapy for Lung Cancer: Recent Development and Perspective. | Immunotargets Ther | 2026 | https://conductscience.org/library/papers/42483566 | PubMed |
| 42450152 | Targeting MET in 2025: From Exon 14 Skipping to MET-Amplified Acquired Resistance in Non-Small Cell Lung Cancer. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42450152 | PubMed |
| 42447248 | Methylation-based liquid biopsy facilitates early detection of small cell transformation in ALK-rearranged non-small cell lung cancer. | Oncologist | 2026 | https://conductscience.org/library/papers/42447248 | PubMed |
| 42444834 | Unmasking biomarkers in small cell lung cancer: implication for precision oncology. | Front Oncol | 2026 | https://conductscience.org/library/papers/42444834 | PubMed |
| 42290055 | [A Case of EGFR-mutant Lung Adenocarcinoma with Secondary SCLC Transformation and ALK Fusion after Osimertinib Treatment]. | Zhongguo Fei Ai Za Zhi | 2026 | https://conductscience.org/library/papers/42290055 | PubMed |
| 42088420 | A Darwinian Perspective on Tumor Evolution. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42088420 | PubMed |
| 42079860 | The evolving landscape of first-line and subsequent therapies in EGFR-mutated NSCLC: efficacy, resistance, and tolerability. | Explor Target Antitumor Ther | 2026 | https://conductscience.org/library/papers/42079860 | PubMed |
Genes21
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data3
The data bank entries PubMed's record names. Trial numbers are under Trials.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25758528
GET https://conductscience.org/api/papers/v1/25758528/authors?page=2